Hashim U. Ahmed | |
|---|---|
| Born | Hashim Uddin Ahmed |
| Nationality | British |
| Citizenship | United Kingdom |
| Scientific career | |
| Fields | Urology, Urological Oncology |
Hashim U. Ahmed is a British surgeon, medical researcher and author of publications in the field of prostate cancer diagnostics and treatment; his research has contributed to changes in the way men with suspected prostate cancer and men with prostate enlargement are diagnosed and treated. [1] He is Professor and Chair of Urology at Imperial College Healthcare NHS Trust [2] and Consultant Urological Surgeon at both Charing Cross Hospital [2] and BUPA Cromwell Hospital. [3]
He studied medicine at Oxford University, graduating with a BA (Hons) in Physiology in 1998 and completing his medical degree (BM, BCh) in 2001 and has been registered with the GMC since 2001. [4] He completed a Postgraduate Diploma in Clinical Trials at the London School of Hygiene and Tropical Medicine in 2010 and a PhD at University College London in 2013, entitled “The Role of Focal Therapy in the Treatment of Prostate Cancer”. [5]
Professor Ahmed currently divides his time between clinical practice and research, [6] practicing at Charing Cross Hospital [2] and BUPA Cromwell Hospital. [3] As a forerunner in the field of prostate conditions, he is one of the few surgeons offering HIFU (High-intensity focused ultrasound) and cryotherapy for prostate cancer as well as Rezüm water vapor thermal therapy (also known as Prostate steam treatment) for patients diagnosed with prostate enlargement in the UK, with minimal side effects. [1] [7] [8]
Professor Ahmed's research interests lie in advancing diagnostics and treatment of prostate cancer and benign prostate enlargement, to improve life expectancy and quality of life for prostate cancer patients. [9] [10] His research has contributed to the implementation of new diagnostic techniques such as advanced imaging, tissue biomarkers and biopsy techniques, to accurately locate cancerous tissue, improve diagnostic accuracy and inform treatment options. [6] [11] [12] [13] As a direct result of his work, the NHS is piloting a Rapid Access to Prostate Imaging and Diagnosis (RAPID) prostate pathway in which patients receive multi-parametric MRI (mp-MRI) scans prior to biopsy. [14] [15] [16] [17] Ahmed has also worked on innovative, non-invasive treatment techniques that target cancer cells whilst preserving healthy tissue and function, thus leading to fewer side-effects; these treatments include focal high intensity focused ultrasound (HIFU), cryotherapy, radiofrequency ablation, injectable toxins, magnetic thermo-ablation and partial ablation rather than full prostate removal. [18] [19] [20] [21]
Urology, also known as genitourinary surgery, is the branch of medicine that focuses on surgical and medical diseases of the urinary system and the reproductive organs. Organs under the domain of urology include the kidneys, adrenal glands, ureters, urinary bladder, urethra, and the male reproductive organs.
The prostate is both an accessory gland of the male reproductive system and a muscle-driven mechanical switch between urination and ejaculation. It is found in all male mammals. It differs between species anatomically, chemically, and physiologically. Anatomically, the prostate is found below the bladder, with the urethra passing through it. It is described in gross anatomy as consisting of lobes and in microanatomy by zone. It is surrounded by an elastic, fibromuscular capsule and contains glandular tissue, as well as connective tissue.
Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder. Abnormal growth of prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels. Those with high levels of PSA in their blood are at increased risk for developing prostate cancer. Diagnosis requires a biopsy of the prostate. If cancer is present, the pathologist assigns a Gleason score, and a higher score represents a more dangerous tumor. Medical imaging is performed to look for cancer that has spread outside the prostate. Based on the Gleason score, PSA levels, and imaging results, a cancer case is assigned a stage 1 to 4. A higher stage signifies a more advanced, more dangerous disease.
Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.
Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), P-30 antigen, is a glycoprotein enzyme encoded in humans by the KLK3 gene. PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland in men and the paraurethral glands in women.
Prostate biopsy is a procedure in which small hollow needle-core samples are removed from a man's prostate gland to be examined for the presence of prostate cancer. It is typically performed when the result from a PSA blood test is high. It may also be considered advisable after a digital rectal exam (DRE) finds possible abnormality. PSA screening is controversial as PSA may become elevated due to non-cancerous conditions such as benign prostatic hyperplasia (BPH), by infection, or by manipulation of the prostate during surgery or catheterization. Additionally many prostate cancers detected by screening develop so slowly that they would not cause problems during a man's lifetime, making the complications due to treatment unnecessary.
Prostate cancer screening is the screening process used to detect undiagnosed prostate cancer in men without signs or symptoms. When abnormal prostate tissue or cancer is found early, it may be easier to treat and cure, but it is unclear if early detection reduces mortality rates.
High-intensity focused ultrasound (HIFU), or MR-guided Focused Ultrasound Surgery is an incision-less therapeutic technique that uses non-ionizing ultrasonic waves to heat or ablate tissue. HIFU can be used to increase the flow of blood or lymph or to destroy tissue, such as tumors, via thermal and mechanical mechanisms. Given the prevalence and relatively low cost of ultrasound generation mechanisms, the premise of HIFU is that it is expected to be a non-invasive and low-cost therapy that can at least outperform care in the operating room.

Cryoablation is a process that uses extreme cold to destroy tissue. Cryoablation is performed using hollow needles (cryoprobes) through which cooled, thermally conductive fluids are circulated. Cryoprobes are positioned adjacent to the target in such a way that the freezing process will destroy the diseased tissue. Once the probes are in place, the attached cryogenic freezing unit removes heat from ("cools") the tip of the probe and by extension from the surrounding tissues.
Urology Robotics, or URobotics, is a new interdisciplinary field for the application of robots in urology and for the development of such systems and novel technologies in this clinical discipline. Urology is among the medical fields with the highest rate of technology advances, which for several years has included the use medical robots.
Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination. Treatments also extend to survivorship based interventions. These interventions are focused on five domains including: physical symptoms, psychological symptoms, surveillance, health promotion and care coordination. However, a published review has found only high levels of evidence for interventions that target physical and psychological symptom management and health promotion, with no reviews of interventions for either care coordination or surveillance. The favored treatment option depends on the stage of the disease, the Gleason score, and the PSA level. Other important factors include the man's age, his general health, and his feelings about potential treatments and their possible side-effects. Because all treatments can have significant side-effects, such as erectile dysfunction and urinary incontinence, treatment discussions often focus on balancing the goals of therapy with the risks of lifestyle alterations.
Roger Sinclair Kirby FRCS(Urol), FEBU is a British retired prostate surgeon and professor of urology, researcher, writer on men's health and prostate disease, founding editor of the journal Prostate Cancer and Prostatic Diseases and Trends in Urology and Men's Health and a fundraiser for prostate disease charities, best known for his use of the da Vinci surgical robot for laparoscopic prostatectomy in the treatment of prostate cancer. He is a co-founder and president of the charity The Urology Foundation (TUF), vice-president of the charity Prostate Cancer UK, trustee of the King Edward VII's Hospital and as of 2020 is president of the Royal Society of Medicine (RSM), London.
Specimen provenance complications (SPCs) result from instances of biopsy specimen transposition, extraneous/foreign cell contamination or misidentification of cells used in clinical or anatomical pathology. If left undetected, SPCs can lead to serious diagnostic mistakes and adverse patient outcomes.
DNA Specimen Provenance Assignment (DSPA) also known as DNA Specimen ProvenanceAssay, is a molecular diagnostic test used to definitively assign biopsy specimen identity and establish specimen purity during the diagnostic testing cycle for cancer and other histopathological conditions. The term first appeared in the 2011 scientific paper, “The Changing Spectrum of DNA-Based Specimen Provenance Testing in Surgical Pathology,” published in the American Journal of Clinical Pathology, which built upon concepts described in an earlier paper published in the Journal of Urology.

Prokar Dasgupta is an Indian-born British surgeon and academic who is professor of surgery at the surgical academy at King's Health Partners, London, UK. Since 2002, he has been consultant urologist to Guy's Hospital, and in 2009 became the first professor of robotic surgery and urology at King's, and subsequently the chairman of the King's College-Vattikuti Institute of Robotic Surgery.
PI-RADS is an acronym for Prostate Imaging Reporting and Data System, defining standards of high-quality clinical service for multi-parametric magnetic resonance imaging (mpMRI), including image creation and reporting.
Caroline M. Moore is the first woman to be made a professor of urology in the United Kingdom. She works in the diagnosis and treatment of prostate cancer at University College London.
The Urology Foundation (TUF) is a charity that works across the UK and Ireland with the aim of improving the knowledge and skills of surgeons who operate on diseases of the male and female urinary-tract system and the male reproductive organs and funds research to improve outcomes of all urological conditions and urological cancers.
Padeliporfin, sold under the brand name Tookad, is a medication used to treat men with prostate cancer. It is used in the form padeliporfin di-potassium.
Mark Emberton is a urologist and prostate cancer research specialist using novel imaging techniques and minimally invasive treatments to improve diagnosis and treatment of prostate cancer.